JP2023539246A - 腫瘍微小環境の遺伝的調節のための方法及び組成物 - Google Patents
腫瘍微小環境の遺伝的調節のための方法及び組成物 Download PDFInfo
- Publication number
- JP2023539246A JP2023539246A JP2023513297A JP2023513297A JP2023539246A JP 2023539246 A JP2023539246 A JP 2023539246A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023539246 A JP2023539246 A JP 2023539246A
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- inhibitor
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070173P | 2020-08-25 | 2020-08-25 | |
| US63/070,173 | 2020-08-25 | ||
| PCT/US2021/047380 WO2022046792A2 (en) | 2020-08-25 | 2021-08-24 | Methods and compositions for genetic modulation of tumor microenvironments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539246A true JP2023539246A (ja) | 2023-09-13 |
| JP2023539246A5 JP2023539246A5 (cg-RX-API-DMAC7.html) | 2024-09-02 |
Family
ID=80355668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513297A Pending JP2023539246A (ja) | 2020-08-25 | 2021-08-24 | 腫瘍微小環境の遺伝的調節のための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220110924A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203955A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023539246A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230057426A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021333655A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023003466A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190514A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002286A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022046792A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202302154B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4654979A1 (en) * | 2023-01-25 | 2025-12-03 | Huyabio International, LLC | Methods and compositions comprising a cardio-tolerated hdac inhibitor |
| CN117357530A (zh) * | 2023-11-07 | 2024-01-09 | 苏州大学附属儿童医院 | Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019519498A (ja) * | 2016-05-11 | 2019-07-11 | フヤ バイオサイエンス インターナショナル エルエルシー | Hdac阻害剤とpd−1阻害剤との組み合わせ療法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244751B2 (en) * | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
-
2021
- 2021-08-24 AU AU2021333655A patent/AU2021333655A1/en active Pending
- 2021-08-24 KR KR1020237010117A patent/KR20230057426A/ko active Pending
- 2021-08-24 MX MX2023002286A patent/MX2023002286A/es unknown
- 2021-08-24 CA CA3190514A patent/CA3190514A1/en active Pending
- 2021-08-24 JP JP2023513297A patent/JP2023539246A/ja active Pending
- 2021-08-24 BR BR112023003466A patent/BR112023003466A2/pt unknown
- 2021-08-24 WO PCT/US2021/047380 patent/WO2022046792A2/en not_active Ceased
- 2021-08-24 EP EP21862586.1A patent/EP4203955A4/en active Pending
- 2021-08-24 US US17/410,459 patent/US20220110924A1/en active Pending
-
2023
- 2023-02-21 ZA ZA2023/02154A patent/ZA202302154B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019519498A (ja) * | 2016-05-11 | 2019-07-11 | フヤ バイオサイエンス インターナショナル エルエルシー | Hdac阻害剤とpd−1阻害剤との組み合わせ療法 |
Non-Patent Citations (2)
| Title |
|---|
| "A Phase 1b/2 Study of the Safety and Efficacy of HBI-8000-Nivolumab Combination in Melanoma (MEL), R", SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC), JPN6025040905, 2018, ISSN: 0005846205 * |
| CANCER CHEMOTHER PHARMACOL, vol. 69, JPN6025040904, 2012, pages 1413 - 1422, ISSN: 0005846206 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4203955A2 (en) | 2023-07-05 |
| CA3190514A1 (en) | 2022-03-03 |
| KR20230057426A (ko) | 2023-04-28 |
| AU2021333655A9 (en) | 2024-06-06 |
| ZA202302154B (en) | 2023-10-25 |
| AU2021333655A1 (en) | 2023-05-04 |
| EP4203955A4 (en) | 2024-09-18 |
| US20220110924A1 (en) | 2022-04-14 |
| WO2022046792A3 (en) | 2022-04-07 |
| MX2023002286A (es) | 2023-05-16 |
| BR112023003466A2 (pt) | 2023-05-09 |
| WO2022046792A2 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7190548B2 (ja) | Hdac阻害剤とpd-l1阻害剤との組み合わせ療法 | |
| US20250026832A1 (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| US20220110924A1 (en) | Methods and compositions for genetic modulation of tumor microenvironments | |
| US20200383961A1 (en) | Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors | |
| WO2024015478A2 (en) | Combination therapies of wdr5 inhibitors and pd-1 inhibitors | |
| JP2026503609A (ja) | 心臓耐容性hdac阻害剤を含む方法および組成物 | |
| HK40129132A (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| WO2025090881A1 (en) | Combination therapies of wdr5 inhibitors and pd-1 inhibitors | |
| EA045229B1 (ru) | Комбинация ингибиторов hdac и pd-1 и её применение для лечения рака толстой кишки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251006 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260126 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260422 |